
US company hopes to transform access to advanced biologics
Phylloceuticals has announced the successful production of its first batch of a PD-1 inhibitor monoclonal antibody (mAb) just 12 weeks after initiating operations in its new laboratory space in Rapid City, South Dakota, US. The company says the achievement marks a potential paradigm shift in how complex… Read More
